Abstract library

59 results for "Apoptosis".
#2834 Tumor-Promoting Effects of the Transcriptional Regulator CUX1 in PanNET
Introduction: Previously, we identified CUX1 as mediator of metastatic behaviour and poor differentiation in human insulinomas. CUX1 mediated tumor-promoting functions via enhancing proliferation, resistance to apoptosis and angiogenesis in-vitro and in-vivo.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Sebastian Krug
#3320 TGF-β increase caspase activation and migration in typical bronchial carcinoids
Introduction: Typical bronchial carcinoids (TBC) are well-differentiated neuroendocrine neoplasms (NEN) whose management can still be very challenging due to reduced sensitivity to therapy. Previous studies have reported TGF-β’s ability to activate mTOR pathway and induce epithelial to mesenchymal transition (EMT). Moreover, preliminary results show an overexpression of TGF-β signalling and caspase activation in TBC.
Conference: 18th Annual ENETS Conference 2021 (2021)
Category: Basic science - Signalling pathways, receptors, biomarkers
Presenting Author: Patricia Borges de Souza
#2682 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D. Candidate Gabriel Mpilla
Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, ...
#2800 Thymosin Beta 4 Is an Autocrine Mitogen for Neuroendocrine Tumour Cells
Introduction: The most commonly used NET marker chromogranin A, has a sensitivity between 60-90% and a specificity of less than 50%, hence better NET markers are needed. Previous secretome analysis using BON1, NCI-H727 and SHP-77 cell lines has led to the discovery of various candidate NET markers. One such marker is Thymosin Beta 4 (TB4). TB4 is a small 43 amino acid intracellular peptide first isolated from bovine thymus tissue.TB4 or its oxidised form TB4SO are thought to play a role in various aspects of cancer biology including tumour invasion, metastasis and apoptosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ponni Balasundaram
#2810 Development of a Personalized Human Immunocompetent Ex-Vivo Model of Neuroendocrine Liver Metastasis Using Precision Cut Tissue Slice Technology
Introduction: Liver metastasis (LM) are very frequent (65-95%) and represent a crucial prognostic factor in patients with gastroenteropancreatic neuroendocrine neoplasms (GEP NENs). The paucity of relevant experimental models has limited the understanding of the pathophysiology of NENs and the development of efficient therapeutic strategies
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Ewald Doornebal
Authors: Doornebal E, Harris N, Miquel R, Zen Y, ...
#2874 Role of FOXM1 in Aggressive Pancreatic / Pulmonary Neuroendocrine Carcinomas and Anti-Tumor Effect of the FOXM1 Inhibitor Thiostrepton
Introduction: DNA-targeting agents are the main treatment of aggressive pulmonary and pancreatic neuroendocrine carcinomas (NEC). FOXM1 is a transcription factor controlling cell proliferation and DNA repair pathways, playing therefore an important role in tumor progression and chemoresistance.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Jerome Cros
#38 Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors
Introduction: Neuroendocrine tumors (NET), especially well-differentiated endocrine tumors, are often slow-growing, indolent, and may not become clinically apparent until the manifestations of metastatic spread or carcinoid syndrome. Results of previous studies demonstrated that phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway may be activated in the great majority of NET cells. mTOR inhibitors are therefore considered effective anti-tumor reagents but they may also induce an activation of PI3K/Akt and MAPK pathways as a compensatory action and reduce their own anti-tumor activities.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Professor Hironobu Sasano
Authors: Iida S, Miki Y, Ono K, Sasano H, ...
#113 Prolonged cell survival in xenografts from human digestive endocrine tumors
Introduction: Gastroenteropancreatic endocrine tumors have the capacity to achieve very large tumor masses despite usually very low proliferative rates. This suggests that neoplastic endocrine cells may have long life spans, implying the development of specific mechanisms able to promote cell survival.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Colette Roche
#119 Valproic acid induces apoptosis-mediated cell death of the ileal carcinoid cell line GOT1
Introduction: Downregulation of tumor suppressor genes, evasion from apoptosis, and reduced differentiation are hallmarks of cancer that can be due to abnormal epigenetic control. Histone deacetylase (HDAC) is an enzyme involved in the deacetylation of histone proteins, resulting in chromatin remodelling and altered gene transcription. HDAC inhibitors are emerging as useful anticancer drugs.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Yvonne Arvidsson
Authors: Arvidsson Y, Ahlman H, Nilsson O, ...
#154 Long-term disease stabilization in a patient with advanced pancreatic neuroendocrine tumor treated with combined everolimus and octreotide LAR after prior failure of cytotoxic therapy
Introduction: Targeting of multiple pathways has become an important strategy for improved tumor control in metastatic neuroendocrine tumors (NETs). Among these targets is the mammalian target of rapamycin (mTOR), a central regulator of cell growth, proliferation, and apoptosis, which is blocked by everolimus, an oral inhibitor of mTOR that has shown efficacy in patients with metastatic pancreatic NETs. Recent evidence has suggested that suppression of insulin-like growth factor-1 receptor (IGF-1R) secretion with octreotide therapy, along with concurrent inhibition of mTOR by everolimus, may improve tumor control synergistically by preventing feedback activation of the PI3K/Akt/mTOR pathway.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Alexandre Teulé Vega